Sector
PharmaceuticalsOpen
₹973Prev. Close
₹972.95Turnover(Lac.)
₹9,022.42Day's High
₹985.2Day's Low
₹970.0552 Week's High
₹1,324.352 Week's Low
₹795Book Value
₹213.58Face Value
₹1Mkt Cap (₹ Cr.)
98,570.68P/E
17.07EPS
57.39Divi. Yield
1.1216 Jun 2025
12:00 AM
Board Meeting
Agenda : Audited Result
17 May 2024
12:00 AM
Dividend
Dividend Amount: 3
Record Date: 26 Jul, 2024
17 May 2024
12:00 AM
AGM
Announcement Date: 17 May, 2024
In its filing with the bourses, Zydus informed that these observations received were minor, and not related to data integrity.
Here are some of the stocks that may see significant price movement today: Jio Financial Service, Hero MotoCorp, Abbott India, etc.
Here are some of the stocks that may see significant price movement today: Hindustan Copper, Maruti Suzuki, Zydus Lifesciences, etc.
For Zydus, this clean report adds a layer of credibility to its US compliance track record especially since the Ankleshwar facility is a key site for its API exports.
The acquisition is priced at $7.50 per share and will be completed in cash within 60 days, subject to regulatory approvals
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 100.6 | 101.2 | 102.4 | 102.4 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 15,615.9 | 13,538.2 | 13,138.1 | 12,642.1 |
Net Worth | 15,716.5 | 13,639.4 | 13,240.5 | 12,744.5 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 7,981.9 | 7,780 | 6,347.4 | 5,809.9 |
yoy growth (%) | 2.59 | 22.56 | 9.25 | 79.83 |
Raw materials | -2,870.2 | -2,351.4 | -1,951.7 | -1,695.7 |
As % of sales | 35.95 | 30.22 | 30.74 | 29.18 |
Employee costs | -1,204.9 | -1,147.3 | -1,077.4 | -826 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,483.2 | 1,876 | 1,609.7 | 1,497.2 |
Depreciation | -478.7 | -451.1 | -428.9 | -293.1 |
Tax paid | -306 | -212.3 | -204.1 | -406.4 |
Working capital | 607.49 | 991.9 | 1,239 | 1,462.2 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 2.59 | 22.56 | 9.25 | 79.83 |
Op profit growth | -16.91 | 62.23 | -13.55 | 412.7 |
EBIT growth | -16.88 | 5.6 | 18.09 | 138.95 |
Net profit growth | -41.88 | 4.48 | 29.52 | 64.79 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 22,573.8 | 19,021.5 | 16,877.8 | 14,827.6 | 14,125 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 22,573.8 | 19,021.5 | 16,877.8 | 14,827.6 | 14,125 |
Other Operating Income | 667.7 | 525.9 | 359.6 | 282.3 | 278.5 |
Other Income | 269.5 | 307.1 | 186.6 | 2,583.1 | 45.6 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,662.5 | 93.33 | 3,99,045.4 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,844.5 | 82.22 | 1,81,611.04 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,477.8 | 24.79 | 1,19,322.68 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,339.4 | 59.72 | 1,13,003.55 | 474 | 0.18 | 2,385 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,262.6 | 19.53 | 1,05,090.54 | 1,200.7 | 0.63 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Pankaj R Patel
Managing Director
Sharvil P Patel
Non Executive Director
Mukesh M Patel
Independent Director
Apurva S Diwanji
Whole-time Director
Ganesh N Nayak
Independent Director
Bhadresh K Shah
Company Sec. & Compli. Officer
Dhaval N Soni
Independent Director
Akhil A. Monappa
Independent Director
Upasana Konidela.
Independent Director
Shelina P. Parikh
Zydus Corporate Park S No 536,
Khoraj Sarkhej-Gandhinagar H/W,
Gujarat - 382481
Tel: 91-079-26868100
Website: http://www.zyduscadila.com
Email: dhavalsoni@zyduscadila.com; upen.shah@zyduscadila.
5th Floor 506 to 508,
ABC-I Off C G Road, Navrangpura,
Ahmedabad-380009
Tel: 91-79-26465179
Website: https://in.mpms.mufg.com/
Email: ipo.team@linkintime.co.in
Summary
Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain i...
Read More
Reports by Zydus Lifesciences Ltd
What is the Zydus Lifesciences Ltd share price today?
What is the Market Cap of Zydus Lifesciences Ltd?
What is the PE and PB ratio of Zydus Lifesciences Ltd?
What is the 52 Week High and Low of Zydus Lifesciences Ltd?
What is the CAGR of Zydus Lifesciences Ltd?
What is the shareholding pattern of Zydus Lifesciences Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
